Kuldip Singh


BACKGROUND: Thyroid diseases with accompanying dyslipidemia is widely recognized as a risk factor for various cardiovascular disease like
atherosclerosis/myocardial infarction, which cannot be fully explained by the atherogenic lipid profile and plasma total homocysteine is an
independent risk factor for the initiation of atherosclerosis.
OBJECTIVE: The aim of this study was to investigate the serum total homocysteine level in subclinical as well as overt hypothyroid patients of
North/West Indians to observe the relationship between lipid, homocysteine and hypothyroidism.
MATERIAL AND METHODS: In the present study, 80 hypothyroid patients (40 sub clinical hypothyroidism and 40 overt hypothyroidism) and
40 normal healthy controls subjects of both sex, with a mean age range 20–50 years from North West Punjabi population were recruited in the
present study for the evaluation of serum total homocysteine along with lipid and lipoproteins levels.
RESULTS: In the present a significant increase in total cholesterol (P ≤ 0.05), triglycerides (P ≤ 0.001), LDL- cholesterol (P ≤ 0.05), and VLDLcholesterol
was observed in sub clinical and overt hypothyroid patients while a significant fall (P ≤ 0.001) in both sub clinical hypothyroidism and
overt hypothyroidism was reported in comparison to normal healthy subjects. A significant (P ≤ 0.001) increase in total homocysteine level was
recorded in overt hypothyroidism but non significantly increased was observed in total homocysteine levels in sub clinical hypothyroidism
CONCLUSION: A strong relationship between serum homocysteine levels and lipid profile concentrations especially the concentrations of total
cholesterol and triglycerides in hypothyroidism might increase cardiovascular risk. So, determination of serum levels of thyroid profile is
recommended in subjects with unexplained Hyperhomocysteinemia.


Subclinical hypothyroidism, overt hypothyroidism, lipids, Lipoproteins, Total homocysteine (tHcy).

Full Text:



Kim, B., 2008. Thyroid hormone as a determinant of energy expenditure and the basal metabolic rate. Thyroid 18 (2), 141–144.

Cachefo, A.N.A., Boucher, P., Vidon, C., Dusserre, E., Diraison, F., Beylot, M., 2001. Hepatic lipogenesis and cholesterol synthesis in hyperthyroid patients. J. Clin. Endocrinol.Metab. 86 (11), 5353–5357.

Beylot, 2001. Hepatic lipogenesis and cholesterol synthesis in hyperthyroid patients. J. Clin. Endocrinol. Metab. 86 (11), 5353–5357.

Duntas, L.H., 2002. Thyroid disease and lipids. Thyroid 12 (4), 287–293. Ekins, R.B., 1978. Free thyroxine hormone. In: Proceeding of the Inter-national Symposium held in Venice.

Bicıkova,M., Hampl, R., Hill, M., et al., 2003. Steroids, sex hormonebinding globulin, homocysteine, selected hormones and markers of lipid and carbohydrate metabolism in patients with severe hypothyroidism and their changes following thyroid hormone supplementation. Clin. Chem. Lab. Med. 41 (3), 284–292.

Targher, G., Bertolini, L., Zenari, L., Cacciatori, V., Muggeo, M., Faccini, G., Zoppini, G., 2000. Cigarette smoking and plasma total homocysteine levels in young adults with type 1 diabetes. Diabetes Care 23, 524–528.

Temple, M.E., Luzier, A.B., Kazierad, D.J., 2000. Homocysteine as a risk factor for atherosclerosis. Ann. Pharmacother. 34, 57–65.

Sakuta, H., Suzuki, T., 2005. Alcohol consumption and plasma homocysteine. Alcohol 372, 73–77.

Yun, K.U., Ryu, C.U., Oh, J.M., Kim, C.H., 2013. Plasma homocysteine level and hepatic sulfur amino acid metabolism in mice fed a high-fat diet. Eur. J. Nutr. 52 (1), 127–134.

Gallai, V., Caso, V., et al., 2001. Mild hyperhomocysteinemia: a possible risk factor for cervical artery dissection. Stroke 32, 714–718.

Papatheodorou, L., Weiss, N., 2007. Vascular oxidant stress and inflammation in hyperhomocysteinemia. Antioxid. Redox Signal.9, 1941–1958.

Hofmann, M.A., Lalla, E., et al., 2001. Hyperhomocysteinemia enhances vascular inflammation and accelerates atherosclerosis in a murine model. J. Clin. Invest. 107, 675–683.

Zeng, X., Dai, J., Remick, D.G., Wang, X., 2003. Homocysteine mediated expression and secretion of monocyte chemoattractant protein-1 and interleukin-8 in human monocytes. Circ. Res. 93, 311–320.

Osanai, T., Fujiwara, N., et al., 2010. Novel pro-atherogenic molecule coupling factor 6 is elevated in patients with stroke: a possible linkage to homocysteine. Ann. Med. 42, 79–86.

Watson, D., 1960. Calorimetric test for cholesterol lipid clearing factor. Clin. Chem. Acta 5, 637.

Fossati, P., Burghen, G.A., Li, H., Hudson, M.M., Kun, L.E., 1982. Serum triglycerides determined calorimetrically with an enzyme that produce hydrogen peroxide. Clin. Chem. 8, 2078–2082.

Freidewald, W.T., Levy, R.I., Fredickson, D.S., 1972. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 18, 499–502.

Assmann, G., Jabs, H., Kohnert, U., Note, W., Schriever, H., 1984. LDL-cholesterol determination in blood serum following precipitation of LDL with polyvinylsulphate. Clin. Chem. Acta 140, 77–83.

Primus, F.J., Kelley, E.A., Hansen, H.J., Goldenberg, D.M., 1988. ‘‘Sandwich’’-type immunoassay of carcinoembryonic antigen in patients receiving murine monoclonal antibodies for diagnosis and therapy. Clin. Chem. 34, 261 436–4).

Chait A, Bierman EL, Albers JJ. 1979. Regulatory role of triiodothyro¬nine in the degradation of low density lipoprotein by cultured human skin fibroblasts. J Clin Endocrinol Metab. 48(5):887–9.

Paoli-Valeri M, Guzman M, Jimenez-Lopez V, Arias-Ferreira A, Brice¬no-Fernandez M, Arata-Bellabarba G. 2005. Perfil lipidico aterogenico en ninos con hipotiroidismo subclinico. AP.62(2):128–34.

Duntas LH, Wartofsky L.2007. Cardiovascular risk and subclinical hy¬pothyroidism: focus on lipids and new emerging risk factors. What is the evidence? Thyroid. 17(11):1075–84.

Vierhapper H, Nardi A, Grosser P, Raber W, Gessl A. 2000. Low-density lipoprotein cholesterol in subclinical hypothyroidism. Thyroid.10(11):981–4.

Hueston WJ, Pearson WS. 2004. Subclinical hypothyroidism and the risk of hypercholesterolemia. Ann Fam Med.2(4):351–5.

Kanaya AM, Harris F, Volpato S, Perez-Stable EJ, Harris T, Bauer DC. 2002. Association between thyroid dysfunction and total cholesterol level in an older biracial population: the health, aging and body composition study. Arch Intern Med.162(7):773–9.

Canaris GJ, Manowitz NR, Mayor G, Ridgway EC. 2000. The Colorado Thyroid Disease Prevalence Study.JAMA.160(4):526.

Walsh JP, Bremner AP, Bulsara MK, O'Leary P, Leedman PJ, Fed¬dema P, et al. 2005. Thyroid dysfunction and serum lipids: a communi¬ty-based study. Clin Endocrinol (Oxf).63(6):670–5.

Lai Y, Wang J, Jiang F, Wang B, Chen Y, Li M, et al. 2011. The relationship between serum thyrotropin and components of metabolic syn¬drome. Endocr J.58(1):23–30.

Morris MS, Bostom AG, Jacques PF, Selhub J, Rosenberg IH. 2001. Hyperhomocysteinemia and hypercholesterolemia associated with hypothyroidism in the third US National Health and Nutrition Examination Survey. Atherosclerosis 155: 195-200.

Ozmen B, Ozmen D, Parildar Z, Mutaf I, Turgan N, Bayindir O. 2006. Impact of renal function or folate status on altered plasma homocysteine levels in hypothyroidism. Endocr J. 53(1):119-24.

Christ-crain M, Meier, Gugliel Metti M, Huberpr, Riesen W, Staub JJ et al., 2003. Elevated C-reactive protein and homocysteine values: cardiovascular risk factors in hypothyroidism? A crosssectional and a double-blind, placebo - controlled trial. Atherosclerosis. 166: 379-386.

Cakal B, Cakal E, Demirbaβ B, Ozkaya M, Karaahmetoβlu S, Serter R, Aral Y.2007. Homocysteine and fibrinogen changes with L-thyroxine in subclinical hypothyroid patients.J Korean Med Sci.22(3): 431-5.


  • There are currently no refbacks.